APA (7th ed.) Citation

ZB, H., E, C., C, M., L, K., O, E., & A, V. (2025). Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials. The Lancet. Infectious diseases, 25(7), e378. https://doi.org/10.1016/S1473-3099(25)00286-5

Chicago Style (17th ed.) Citation

ZB, Harboe, Cordero E, Moran C, Kuijpers L, Epaulard O, and Vollaard A. "Need for Inclusion of High-risk Populations and Standardisation of Immunogenicity Outcomes in Adult Pneumococcal Vaccine Trials." The Lancet. Infectious Diseases 25, no. 7 (2025): e378. https://doi.org/10.1016/S1473-3099(25)00286-5.

MLA (9th ed.) Citation

ZB, Harboe, et al. "Need for Inclusion of High-risk Populations and Standardisation of Immunogenicity Outcomes in Adult Pneumococcal Vaccine Trials." The Lancet. Infectious Diseases, vol. 25, no. 7, 2025, p. e378, https://doi.org/10.1016/S1473-3099(25)00286-5.